Emerging mechanisms of enzalutamide resistance in prostate cancer

@article{Claessens2014EmergingMO,
  title={Emerging mechanisms of enzalutamide resistance in prostate cancer},
  author={Frank Claessens and Christine Helsen and Stefan Prekovic and Thomas Van den Broeck and Lien Spans and Hendrik van Poppel and Steven Joniau},
  journal={Nature Reviews Urology},
  year={2014},
  volume={11},
  pages={712-716}
}
The majority of prostate cancers are hormone-dependent at diagnosis highlighting the central role of androgen signalling in this disease. Surprisingly, most forms of castration-resistant prostate cancer (CRPC) are still dependent on the androgen receptor (AR) for survival. Therefore, the advent of new AR-targeting drugs, such as enzalutamide, is certainly beneficial for the many patients with metastatic CRPC. Indeed, this compound provides a substantial survival benefit—but it is not curative… Expand
Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
TLDR
A concise overview of the clinical development, use and effectiveness of enzalutamide in the treatment of advanced prostate cancer is provided, translational research addressing enzalUTamide response vs resistance is described and novel potential treatment strategies in the enzyme-resistant setting are highlighted. Expand
The evolving role of enzalutamide on the treatment of prostate cancer.
TLDR
The milestones in the development of enzalutamide in patients with prostate cancer are summarized and special focus is placed on the results of the STRIVE Phase II clinical trial comparing head to head enzalUTamide and bicalutamide on patients with nonmetastatic and mCRPC who have failed androgen deprivation. Expand
Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide
TLDR
The aim of this review is to summarize the main data available on the evaluation of the multiple levels of development of resistance to next-generation AR-directed therapies. Expand
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
TLDR
The pharmacological characteristics of enzalutamide, the efficacy studies which led to its approval, its safety profile, and quality of life-related parameters are reviewed as well as its place in the sequential treatment and management of metastatic prostate cancer are reviewed. Expand
Androgen–glucocorticoid interactions in the era of novel prostate cancer therapy
TLDR
Understanding the biological role of glucocorticoid-related mechanisms that can cause iatrogenic stimulation of prostate cancer growth have emerged, which might contribute to drug resistance and disease progression despite optimal ADT. Expand
Targeting molecular resistance in castration-resistant prostate cancer
TLDR
Current knowledge of mechanisms of resistance to the currently approved treatments, development of adjunctive therapies, and identification of new pathways being targeted for therapeutic purposes are reviewed. Expand
Enzalutamide in Metastatic Castration Resistant Prostate Cancer
TLDR
Enzalutamide is approved for treatment of patients with mCRPC, either in docetaxel-naive or -resistant disease, and several resistance mechanisms involving the androgen-signaling pathway have been identified. Expand
Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
TLDR
Multiple mechanisms of resistance to ADT and currently approved CRPC treatments will help guide future research into targeted therapies, and some of the mechanisms by which these agents fail are unique, many share similarities to the mechanisms contributing to CRPC progression. Expand
Inhibition of Serum Response Factor Improves Response to Enzalutamide in Prostate Cancer
TLDR
This study tested SRF inhibition in vitro and in vivo to assess SRF as a potential target in Castrate-resistant prostate cancer and supports the use of SRF inhibitors to improve response to enzalutamide. Expand
Androgen receptor antagonists produced by Streptomyces overcome resistance to enzalutamide
TLDR
There is an urgent need to develop new AR antagonists with new structures that show potent AR antagonist activity in prostate cancer cells and could overcome resistance to enzalutamide. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 47 REFERENCES
ARN-509: a novel antiandrogen for prostate cancer treatment.
TLDR
ARS-509 exhibits characteristics predicting a higher therapeutic index with a greater potential to reach maximally efficacious doses in man than current AR antagonists, and offers preclinical proof of principle for ARN-509 as a promising therapeutic in bothCastration-sensitive and castration-resistant forms of prostate cancer. Expand
Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
TLDR
This work identifies induction of glucocorticoid receptor (GR) expression as a common feature of drug-resistant tumors in a credentialed preclinical model and establishes a mechanism of escape from AR blockade through expansion of cells primed to drive AR target genes via an alternative nuclear receptor upon drug exposure. Expand
Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.
TLDR
The observed subcellular shift of AR from the nucleus and increased testosterone concentration provide the first evidence in humans that enzalutamide suppresses AR signaling while inducing an adaptive feedback, which is linked to a pretreatment androgen-signaling signature. Expand
Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.
TLDR
This review focuses on the etiology, characterization, biological properties, and emerging data contributing to the clinical characteristics of AR variants, and suggests approaches to full-length AR and AR variant biomarker validation, assessment, and systemic targeting in the clinic. Expand
Adaptation or selection—mechanisms of castration-resistant prostate cancer
TLDR
Current research is focused on not only understanding the cellular mechanisms of CRPC, but also defining critical pathways that can be targeted with combinatorial therapies in castration-resistant cancer cells. Expand
Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
TLDR
This study shows that cells with AR gene rearrangements expressing both full-length and AR-Vs are androgen independent and enzalutamide resistant, but selective knock-down of AR-V expression inhibited androgen-independent growth and restored responsiveness to androgens and antiandrogens. Expand
AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer.
TLDR
Findings indicate that ARv567es could induce tumorigenesis de novo and signifies the critical role of AR-Vs in CRPC, and the Pb-ARv 567es mouse could provide a novel model in which the roles of AR variants in prostate cancer progression can be examined. Expand
Androgen receptor (AR) aberrations in castration-resistant prostate cancer
TLDR
Interestingly, these aberrations lead to activation of the receptor, despite treatment-induced emergence of therapy-resistant tumor clones, indicating that CRPCs remain androgen-sensitive. Expand
Increased survival with enzalutamide in prostate cancer after chemotherapy.
TLDR
Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer after chemotherapy, and was shown with respect to all secondary end points. Expand
Implementing newer agents for the management of castrate‐resistant prostate cancer: what is known and what is needed?
TLDR
Suggestions are provided on the continued relevance of conventional approaches to first‐ and second‐line treatment in mCRPC, the potential role of novel treatments, and factors that may influence the choice of hormonal agents and/or chemotherapy. Expand
...
1
2
3
4
5
...